

## Positive Tuberculin Skin Test (TST) / Interferon Gamma Release Assay (IGRA) Reporting Form

If Tuberculosis (TB) disease is suspected, notify the Health Unit **immediately** at 705-474-1400 or 1-800-563-2808, ext. 5229.

Client Demographics							
Clie	nt's Name:			Current Address:			
Date of Birth:				City:			
☐ Male ☐ Female ☐ Other:				Postal Code:			
Health Card Number:				Canadian Aboriginal: ☐ Yes ☐ No			
Email Address:				Country of Birth:			
Telephone Number:			Date Arrived in Canada:				
Par	Parent/Guardian (if child) / Next of Kin:						
Telephone Number (if different than client):							
<b>Tuberculin Skin Testing (TST)</b> Under the HPPA, all positive TSTs are to be reported to the Medical Officer of Health within 7 days; please fax this form to <b>705-482-0670.</b>							
Reason for testing: ☐ School ☐ Work ☐ Volunteer ☐ Other (Specify):							
	Date Given	Date Read		Result (mm of induration)			
Previous TST: ☐ Yes ☐ No ☐ Unknown							
History of Bacille Calmette-Guérin (BCG) Vaccine: ☐ Yes ☐ No ☐ Unknown → If yes, age when received:							
Scar seen: ☐ Yes ☐ No ☐ Unknown							
Medical Assessment							
Previous/Current IGRA testing done: $\square$ Yes $\square$ No $\rightarrow$ If yes, result: (include copy of report)						de copy of report)	
Human Immunodeficiency Virus (HIV) testing done: ☐ Yes ☐ No If yes, result:							
TB Symptom Onset Date				TB Symptom		Onset Date	
	*Ensure symptoms are related to this illness and do not have an alternative cause.						
	Asymptomatic			Cough lasting lo	onger than 2 weeks		
	Fever/Chills		☐ Productive Cough				
	Night Sweats			Non-Productive	Cough		
	Chest Pain			Loss of Appetite	2		
	Hemoptysis			Unexplained W	eight Loss		
	Other (specify):			l			
Chest X-Ray - fax chest x-ray report, once available, to 705-482-0670							
Chest x-ray ordered/requisition given: ☐ Yes ☐ No Date:							
Sputum - fax results, once available, to 705-482-0670							
#1 Sample Date of Collection:			Result:				
#2 Sample Date of Collection:			Result:				
#3 Sample Date of Collection:			Result:				
Follow-Up							
Referred to client's healthcare provider or specialist:   Yes   Name:							
				Reporting Facility/Office Name:			
Phone Number:			Fax:				
Signature:			Date:				
Will LTBI treatment be initiated?			□ No, specify reason:				
See next page for risk factors to consider.			☐ Yes, fax a copy of the prescription to <b>705-482-0670</b> ,				
			medications to treat TB infection are <b>free</b> from the Health Unit.				

WIF-CDC-102-05 – 2025-01-24 Page 1 of 2



## The following websites can be used as an aid in interpreting TST or IGRA results:

- The online TST/IGRA Interpreter: <a href="https://tstin4d.com/calc.html">https://tstin4d.com/calc.html</a>
- TST Guide: <a href="https://www.myhealthunit.ca/en/health-professionals-and-partners/tuberculin-skin-testing-guide.aspx">https://www.myhealthunit.ca/en/health-professionals-and-partners/tuberculin-skin-testing-guide.aspx</a>.

Neither TST or IGRA can distinguish between TB infection or TB disease. When someone being screened for TB infection tests positive with TST and/or IGRA, further testing is required to rule out TB disease (Campbell et al., 2022). At minimum, the initial assessment should include a clinical assessment and chest x-ray. If abnormalities are detected, then TB preventative treatment (TPT) should be deferred until negative mycobacterial sputum culture results are obtained (Alvarez et al., 2022). To obtain specimens for *mycobacterium* testing, three sputum specimens (spontaneous of induced) should be collected on the same day, a minimum of 1 hour apart (Behr et al., 2022; PHO, 2025).

If the client is diagnosed with TB infection, there is an option to initiate TPT, which can provide important individual and public health benefits if given to people at high risk of developing active TB disease (see below list of risk factors). Medications for TB disease and TB infection are provided <u>free of charge</u> to all clients by the Health Unit. Please consult Chapter 6: Tuberculosis Preventative Treatment in Adults of the Canadian TB Standards, 8<sup>th</sup> Edition for TPT regimens.

Risk factors for developing TB disease for those infected with Mycobacterium tuberculosis:

RISK factors for developing 1B disease for those infected with <i>Mycobacterium tuberculosis:</i>				
	People living with Human Immunodeficiency Virus (HIV)			
Very High Risk	Child or adolescent (<18 y) tuberculosis contact			
very nigh kisk	Adult (≥ 18 y) tuberculosis contact			
	Silicosis			
	Stage 4 or 5 chronic kidney disease with or without dialysis			
	Transplant recipients (solid organ or hematopoietic)			
High Risk	Fibronodular disease			
	Receiving immunosuppressing drugs (e.g., tumor necrosis factor alpha inhibitors or steroids)*			
	Cancer (lung, sarcoma, leukemia, lymphoma or gastrointestinal)			
	Granuloma on chest x-ray			
Moderate Risk	Diabetes			
Widderate Risk	Heavy alcohol use (at least 3 drinks/day)			
	Heavy tobacco cigarette smoker (at least 1 pack/day)			
Low Risk	General (adult) population with no known risk factor			
LOW NISK	Persons with a positive two-step TST booster and no known risk factor			

<sup>\*</sup>Risk does not appear significantly elevated with low-dose steroids (i.e., prednisone), but elevated with moderate or high dose (low dose: ≤ 9mg/day; medium dose: 10-19mg/day; and high dose: ≥20mg/day). (Campbell et al., 2022)

## References

- Alvarez, G. G., Pease, C., & Menzies, D. (2022). Chapter 6: Tuberculosis preventive treatment in adults. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 6*(sup1), 77–86. <a href="https://doi.org/10.1080/24745332.2022.2039498">https://doi.org/10.1080/24745332.2022.2039498</a>
- Behr, M. A., Lapierre, S. G., Kunimoto, D. Y., Lee, R. S., Long, R., Sekirov, I., ... Turenne, C. Y. (2022). Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, 6(sup1), 33–48. <a href="https://doi.org/10.1080/24745332.2022.2035638">https://doi.org/10.1080/24745332.2022.2035638</a>
- Campbell, J. R., Pease, C., Daley, P., Pai, M., & Menzies, D. (2022). Chapter 4: Diagnosis of tuberculosis infection. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 6*(sup1), 49–65. <a href="https://doi.org/10.1080/24745332.2022.2036503">https://doi.org/10.1080/24745332.2022.2036503</a>
- Public Health Ontario (PHO) (2025). Test Information Index: Mycobacterium Culture. Retrieved from: https://www.publichealthontario.ca/en/Laboratory-Services/Test-Information-Index/Mycobacterium-Culture

WIF-CDC-102-05 – 2025-01-24 Page 2 of 2

<sup>&</sup>quot;This information is being collected pursuant to the Health Protection and Promotion Act, R.S.O.1990, c.H.7 and will be retained, used, disclosed, and disposed of in accordance with the Municipal Freedom of Information and Protection of Privacy Act, R.S.O. 1990, c.M.56, the Personal Health Information Protection Act, 2004, S.O.c.3 and all applicable federal and provincial legislation and regulations governing the collection, retention, use, disclosure, and disposal of information. Any questions regarding this collection may be directed to the Personal Health Information Manager at the North Bay Parry Sound District Health Unit, 345 Oak St. W., North Bay, ON P1B 2T2, 705-474-1400 / 1-800-563-2808 or at privacy@healthunit.ca."